Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VQW-765 in Performance Anxiety
NCT04800237Phase 2Completed
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Feb 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AQW051 in performance anxiety, sponsored by Vanda Pharmaceuticals Inc.. Started Feb 2021; status: completed.
02
Drugs
AQW051
03
Conditions
performance anxiety
Beyond the preview
Go deeper on NCT04800237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04800237.